# Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia

> **NCT02832037** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 509 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** BI 425809 dose 1
- **DRUG:** BI 425809 dose 2
- **DRUG:** BI 425809 dose 3
- **DRUG:** BI 425809 dose 4
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02832037
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-25
- **Primary completion:** 2019-12-27
- **Final completion:** 2020-01-29
- **Target enrollment:** 509 (ACTUAL)
- **Last updated:** 2021-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02832037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02832037, "Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02832037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*